Nimotuzumab Cervical Cancer Survival – Clinical Trial Results
Nimotuzumab Shows Promise as First-Line Therapy for Recurrent or Persistent Cervical Cancer
A recent phase 3 study has unveiled promising results for nimotuzumab when used in combination with chemotherapy as a first-line treatment for patients with recurrent or persistent cervical squamous cell carcinoma. The findings suggest that this combination therapy is not only effective but also well-tolerated, offering a potential new avenue for patients facing this challenging diagnosis.
Study Design and Patient Demographics
The multi-center, randomized, double-blind, and controlled study, presented at the 2025 ASCO Annual Meeting (Abstract 5510), evaluated the efficacy and safety of nimotuzumab plus chemotherapy compared to placebo plus chemotherapy. The study enrolled 118 patients with stage IVB, recurrent, or persistent cervical squamous cell carcinoma.
The patient population exhibited a range of disease characteristics:
Stage: 31.36% had stage IVB disease, while 68.64% had recurrent or persistent disease.
Treatment History: 47.46% of patients received prior chemoradiotherapy, and 52.54% received concurrent chemoradiotherapy.
Disease Differentiation: 31.36% had poorly differentiated disease, 27.97% had moderately differentiated disease,and 4.24% had well-differentiated disease. A notable portion, 36.44%, had unknown disease differentiation.
Additional Efficacy Findings and Safety Data
The study revealed a significant overall survival (OS) benefit for patients treated with nimotuzumab. In the investigational arm (n = 51), the median OS was 21.7 months (95% CI, 21.1-32.9), compared to 12.4 months (95% CI, 8-21.4) in the placebo arm (n = 58). This translates to a hazard ratio (HR) of 0.62 (95% CI, 0.39-0.98), with a statistically significant p-value of .04.
An OS benefit was observed across moast prespecified subgroups. Notably, the most pronounced benefits favoring the nimotuzumab arm were seen in:
patients aged 60 years or older (HR, 0.48; 95% CI, 0.13-1.83; P = .28).
Patients with poorly differentiated disease (HR, 0.55; 95% CI, 0.24-1.27; P = .16).
Patients with more than one organ lesion (HR, 0.65; 95% CI, 0.36-1.20; P = .17).
While the p-values in these specific subgroups did not reach statistical significance, the trend towards improved survival is encouraging.
Regarding safety, the combination therapy demonstrated a manageable toxicity profile. Grade 3 or higher adverse effects (AEs) occurred in 78.2% of patients in the investigational arm and 71.4% in the control arm. serious AEs were reported at rates of 14.5% and 20.6%, respectively. Importantly, no AEs led to death in either arm.The most common AEs in the nimotuzumab arm included anemia (41.8%), leukopenia (36.4%),nausea (29.1%),and alopecia (20.0%). In the control arm, these were reported at rates of 0%, 26.9%, 30.0%,and 31.7%, respectively.
When focusing on treatment-related AEs (TRAEs), the most common grade 3 or higher events in the nimotuzumab arm were neutropenia (69%), leukopenia (47%), decreased hemoglobin levels (5%), and decreased platelet counts (5%). In the control arm, the most frequent grade 3 or higher TRAEs were neutropenia (49%), leukopenia (32%), and hypertension (6%).
“The